EE03378B1 - Oral dosage form containing magnesium salt of omeprazole - Google Patents
Oral dosage form containing magnesium salt of omeprazoleInfo
- Publication number
- EE03378B1 EE03378B1 EE9700014A EE9700014A EE03378B1 EE 03378 B1 EE03378 B1 EE 03378B1 EE 9700014 A EE9700014 A EE 9700014A EE 9700014 A EE9700014 A EE 9700014A EE 03378 B1 EE03378 B1 EE 03378B1
- Authority
- EE
- Estonia
- Prior art keywords
- omeprazole
- dosage form
- oral dosage
- magnesium salt
- form containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9400679 | 1994-07-08 | ||
PCT/SE1995/000816 WO1996001622A1 (en) | 1994-07-08 | 1995-07-03 | New oral pharmaceutical formulation containing magnesium salt of omeprazole |
Publications (2)
Publication Number | Publication Date |
---|---|
EE9700014A EE9700014A (en) | 1997-06-16 |
EE03378B1 true EE03378B1 (en) | 2001-04-16 |
Family
ID=20393105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EE9700014A EE03378B1 (en) | 1994-07-08 | 1995-07-03 | Oral dosage form containing magnesium salt of omeprazole |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0768872A1 (en) |
KR (1) | KR970704426A (en) |
BR (1) | BR9508261A (en) |
CA (1) | CA2193681A1 (en) |
CZ (1) | CZ379596A3 (en) |
EE (1) | EE03378B1 (en) |
FI (1) | FI970058A0 (en) |
HU (1) | HUT78132A (en) |
IS (1) | IS4398A (en) |
MX (1) | MX9700152A (en) |
NO (1) | NO970036L (en) |
NZ (1) | NZ289958A (en) |
PL (1) | PL181265B1 (en) |
SK (1) | SK166096A3 (en) |
WO (1) | WO1996001622A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9500478D0 (en) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US5900258A (en) * | 1996-02-01 | 1999-05-04 | Zeolitics Inc. | Anti-bacterial compositions |
SI9700186B (en) | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Novel pharmaceutical preparation with controlled release of active healing substances |
US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6096340A (en) | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
SE9704870D0 (en) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
SE9704869D0 (en) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
SE9802973D0 (en) | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
US6316020B1 (en) * | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
AU3762801A (en) * | 2000-03-09 | 2001-09-17 | Andrew Ilchyshyn | Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor |
EP1133987A1 (en) * | 2000-03-09 | 2001-09-19 | Ian Whitcroft | Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor |
EP1552833B1 (en) * | 2002-10-16 | 2016-12-28 | Takeda Pharmaceutical Company Limited | Process for producing an amorphous optically active isomer of lansoprazole |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
AU2005257977A1 (en) * | 2004-06-15 | 2006-01-05 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical formulations of benzimidazole compounds |
CN105106168B (en) * | 2015-08-19 | 2018-03-06 | 德州德药制药有限公司 | A kind of esomeprazole magnesium intestines capsule and preparation method thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
JPH0768125B2 (en) * | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | Oral formulation of acid labile compounds |
SE9302395D0 (en) * | 1993-07-09 | 1993-07-09 | Ab Astra | NEW PHARMACEUTICAL FORMULATION |
SE9302396D0 (en) * | 1993-07-09 | 1993-07-09 | Ab Astra | A NOVEL COMPOUND FORM |
-
1995
- 1995-07-03 EE EE9700014A patent/EE03378B1/en not_active IP Right Cessation
- 1995-07-03 BR BR9508261A patent/BR9508261A/en not_active Application Discontinuation
- 1995-07-03 HU HU9700039A patent/HUT78132A/en unknown
- 1995-07-03 CA CA002193681A patent/CA2193681A1/en not_active Abandoned
- 1995-07-03 MX MX9700152A patent/MX9700152A/en unknown
- 1995-07-03 WO PCT/SE1995/000816 patent/WO1996001622A1/en not_active Application Discontinuation
- 1995-07-05 CZ CZ963795A patent/CZ379596A3/en unknown
- 1995-07-05 SK SK1660-96A patent/SK166096A3/en unknown
- 1995-07-05 KR KR1019970700059A patent/KR970704426A/en not_active Application Discontinuation
- 1995-07-05 NZ NZ289958A patent/NZ289958A/en unknown
- 1995-07-05 PL PL95318464A patent/PL181265B1/en unknown
- 1995-07-05 EP EP95926067A patent/EP0768872A1/en not_active Withdrawn
-
1996
- 1996-12-17 IS IS4398A patent/IS4398A/en unknown
-
1997
- 1997-01-06 NO NO970036A patent/NO970036L/en not_active Application Discontinuation
- 1997-01-07 FI FI970058A patent/FI970058A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX9700152A (en) | 1997-04-30 |
HUT78132A (en) | 2000-06-28 |
IS4398A (en) | 1996-12-17 |
HU9700039D0 (en) | 1997-02-28 |
EP0768872A1 (en) | 1997-04-23 |
FI970058A (en) | 1997-01-07 |
FI970058A0 (en) | 1997-01-07 |
WO1996001622A8 (en) | 1999-12-23 |
KR970704426A (en) | 1997-09-06 |
NO970036D0 (en) | 1997-01-06 |
WO1996001622A1 (en) | 1996-01-25 |
AU2994795A (en) | 1996-02-09 |
BR9508261A (en) | 1997-12-23 |
NZ289958A (en) | 1998-09-24 |
PL318464A1 (en) | 1997-06-09 |
AU695723B2 (en) | 1998-08-20 |
EE9700014A (en) | 1997-06-16 |
CZ379596A3 (en) | 1997-08-13 |
CA2193681A1 (en) | 1996-01-25 |
PL181265B1 (en) | 2001-06-29 |
NO970036L (en) | 1997-01-06 |
SK166096A3 (en) | 1997-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69634053D1 (en) | Oral drug composition containing 2-methyl-thienobenzodiazepine | |
EE03378B1 (en) | Oral dosage form containing magnesium salt of omeprazole | |
PT754061E (en) | NEW FORM OF ORAL PHARMACEUTICAL DOSAGE | |
NO934547D0 (en) | Oral treatment of Helicobacter-in-infection | |
DK0936913T3 (en) | Oral pharmaceutical composition containing ibandronate | |
EE200000395A (en) | Oral pharmaceutical pulsatile dosage form | |
DE69327902D1 (en) | Dental floss | |
ITMI921123A0 (en) | ORAL PHARMACEUTICAL FORMULATIONS CONTAINING ANTHOCYANOSIDS | |
DE69226936D1 (en) | Pharmaceutical compositions containing hydroxamate derivatives for iron removal | |
ATA65293A (en) | DENTAL ARTICULATOR | |
ITMI932014A0 (en) | EFFERVESCENT ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING ESTRONE | |
DE69219146D1 (en) | ORAL INHALATOR | |
DK0831820T3 (en) | Oral pharmaceutical composition of piperidinoalkanol compounds in solution form | |
ATA65393A (en) | DENTAL ARTICULATOR | |
SE9402433D0 (en) | New oral pharmaceutical dosage form | |
DE9210037U1 (en) | Dental articulator | |
DE9207731U1 (en) | Dental articulator | |
DE9205970U1 (en) | Dental articulator | |
DE9214267U1 (en) | Dental articulator | |
IL105714A0 (en) | Oral dosage forms of risedronate | |
DK135992D0 (en) | DISPOSABLE ORAL PROJECT | |
SE9402925D0 (en) | Novel oral pharmaceutical composition | |
FI965187A0 (en) | Therapeutic compositions containing 3-phenyl-3-hydroxypiperidines | |
DK533989D0 (en) | ORAL DOSAGE FORM | |
SE9402432D0 (en) | New pharmaceutical dosage form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB4A | Valid patent at the end of a year |
Effective date: 20021231 |
|
MM4A | Lapsed by not paying the annual fees |
Effective date: 20020703 |